Viral vectors got the cargo in. LNPs made it manufacturable. The next generation is decided by precision and safety of delivery. Harmony Tao Biotech pairs proprietary ionizable lipids with a ligand library to design targeted delivery for liver, spleen, lung and other non-liver tissues.
mRNA 疫苗完成了核酸药物的产业化验证。基因编辑、体内细胞治疗、蛋白替代疗法正在把核酸药物推向更广阔的治疗场景 —— 而每一种新场景，都对递送的「组织选择性」与「安全性」提出更高要求。
mRNA vaccines industrialised nucleic acid drugs. Gene editing, in vivo cell therapy and protein replacement are now pushing them into far broader indications — and every new indication raises the bar on tissue selectivity and safety of delivery.
遗传病、肿瘤及代谢性疾病
Genetic, oncology & metabolic disease
致病基因修复、沉默或调控
Repair, silence or modulate the disease-causing gene
肿瘤、自身免疫病、再生医学
Oncology, autoimmune disease, regenerative medicine
改造免疫细胞或干细胞，增强靶向杀伤或修复功能
Engineer immune or stem cells for targeted killing or repair
罕见病、慢性病
Rare and chronic disease
补充缺失或缺陷蛋白
Restore missing or defective proteins
传染病预防
Infectious disease prevention
表达抗原并诱导特异性免疫应答
Express antigen and induce specific immune response
('AAV / LV 载体转导高效、表达持久，是基因编辑的成熟路线，但存在免疫原性、大剂量给药的安全隐患与规模化生产瓶颈。行业迫切需要「非病毒、可重复给药」的递送方案。', 'AAV and lentiviral vectors transduce efficiently and express durably, but carry immunogenicity, dose-related safety concerns and manufacturing bottlenecks. The field needs a non-viral route that can be re-dosed.')
AAV and lentiviral vectors transduce efficiently and express durably, but carry immunogenicity, dose-related safety concerns and manufacturing bottlenecks. The field needs a non-viral route that can be re-dosed.
('目前成熟的 LNP 应用集中在静脉肝靶向与肌注疫苗。脾、肺、背根神经节等组织与特定细胞类型的靶向递送，仍是限制核酸疗法边界的关键瓶颈 —— 这正是道一的切入点。', "Today's mature LNP applications are intravenous liver targeting and intramuscular vaccines. Spleen, lung, dorsal root ganglion and defined cell types remain the bottleneck that limits how far nucleic acid therapy can reach — this is exactly where Harmony Tao works.")
Today's mature LNP applications are intravenous liver targeting and intramuscular vaccines. Spleen, lung, dorsal root ganglion and defined cell types remain the bottleneck that limits how far nucleic acid therapy can reach — this is exactly where Harmony Tao works.
同一个脂质材料平台，三种给药路径，解决三类临床未满足需求。
One lipid platform, three administration routes, three unmet clinical needs.
A lipid library, a ligand library, the Lipoeasy® validation tool and a T-LNP in vitro / in vivo database are fused into one reusable delivery design engine, with AI in vitro and in vivo models turning formulation screening from trial-and-error into prediction.
基因编辑疗法
Gene editing
体内细胞治疗
In vivo cell therapy
('一体化递送设计服务：脂质材料定制 · LNP 处方筛选 · 理化表征 · 体内外转染验证 · 动物药效评价。', 'End-to-end delivery design: custom lipid synthesis, LNP formulation screening, physicochemical characterisation, in vitro / in vivo transfection and animal efficacy evaluation.')
End-to-end delivery design: custom lipid synthesis, LNP formulation screening, physicochemical characterisation, in vitro / in vivo transfection and animal efficacy evaluation.
